Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
182 studies found for:    abiraterone
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants
Condition: Healthy
Interventions: Drug: Treatment A: abiraterone acetate;   Drug: Treatment B: abiraterone acetate;   Drug: Treatment C: abiraterone acetate
2 Completed A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants
Condition: Healthy
Interventions: Drug: Abiraterone acetate;   Drug: Rifampicin
3 Completed Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
Condition: Healthy
Interventions: Drug: Abiraterone acetate (Treatment A);   Drug: Abiraterone acetate (Treatment B)
4 Completed A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
Condition: Healthy Participants
Interventions: Drug: Abiraterone acetate, 250 mg (uncoated, current commercial tablet);   Drug: Abiraterone acetate, 500 mg (coated, reformulated tablet);   Drug: Abiraterone acetate, 250 mg (coated, reformulated tablet);   Drug: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
5 Completed A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men
Condition: Healthy Volunteers
Interventions: Drug: Period 1: Abiraterone;   Drug: Period 2: Abiraterone/Ketoconazole
6 Completed A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
7 Recruiting Abiraterone Acetate for Castrate Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: Prednisone
8 Active, not recruiting A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone;   Other: Androgen deprivation therapy (ADT);   Drug: Abiraterone acetate Placebo;   Drug: Prednisone Placebo
9 Active, not recruiting A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Conditions: Metastatic ER+ Her2- Breast Cancer;   Postmenopausal
Interventions: Drug: Exemestane;   Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane;   Drug: Abiraterone acetate + Prednisone or Prednisolone
10 Completed A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone;   Drug: Dextromethorphan hydrobromide;   Drug: Theophylline
11 Completed
Has Results
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: prednisone/prednisolone or dexamethasone
12 Completed A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men
Condition: Pharmacology
Interventions: Drug: Abiraterone: Treatment A;   Drug: Abiraterone: Treatment B;   Drug: Abiraterone: Treatment C;   Drug: Abiraterone: Treatment D
13 Recruiting RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
Condition: Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Testosterone Enanthate;   Drug: Abiraterone acetate;   Drug: Enzalutamide
14 Recruiting Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone
Condition: Prostate Cancer
Intervention: Drug: Abiraterone
15 Completed
Has Results
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostate Neoplasms;   Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: Prednisone
16 Terminated A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Condition: Castrate-resistant Prostate Cancer Patients.
Interventions: Drug: BEZ235;   Drug: Prednisone;   Drug: Abiraterone acetate
17 Completed A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function
Condition: Renal Insufficiency
Interventions: Drug: Abiraterone acetate: participants with end-stage renal disease;   Drug: Abiraterone acetate: matched control participants with normal renal function
18 Active, not recruiting Abiraterone Acetate Trial in African American Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: Abiraterone Acetate
19 Recruiting Sequencing Abiraterone and Enzalutamide in mCRPC
Condition: Metastatic Castration-Resistant Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Enzalutamide
20 Completed A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years